Preimplantation Genetic Diagnosis (PGD) by Array Comparative Genome Hybridization (CGH) and Blastocyst Biopsy
Launched by REPROGENETICS · Apr 8, 2011
Trial Information
Current as of August 02, 2025
Terminated
Keywords
ClinConnect Summary
Rational for the study:
The goal of this study is to determine if the strategy employed for the Test group can solve two major problems in ART, one the still low implantation rate in women of advanced maternal age, and two the frequent occurrence of multiple pregnancies resulting from solving the first problem by replacing too many embryos.
Preimplantation Genetic Diagnosis (PGD) has been proposed as a potential means to achieve these goals, but so far, the results with day 3 biopsy and FISH analysis of 5-12 chromosomes has produced contradictory results, the difference between studies be...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Couples with women 30-42 years of age
- • Follicle Stimulating Hormone (FSH) level \<11IU/L on day 3 of cycle.
- Exclusion Criteria:
- • TESA and TESE patients
- • Couples' carriers of chromosomal or genetic diseases
- • Couples that produce less than eight antral follicles on day 2-4 of cycle
- • Patients will be excluded if they produce no blastocysts by day 5
About Reprogenetics
Reprogenetics is a leading clinical trial sponsor specializing in advanced reproductive technologies and genetic testing solutions. With a commitment to enhancing patient outcomes in reproductive health, the organization focuses on innovative approaches to preimplantation genetic diagnosis (PGD), preimplantation genetic screening (PGS), and other cutting-edge methodologies. Reprogenetics collaborates with fertility clinics and research institutions to conduct rigorous clinical trials, ensuring the highest standards of safety, efficacy, and ethical practice. Their expertise in genetic analysis and reproductive medicine positions them at the forefront of developing personalized solutions for individuals and couples seeking to optimize their reproductive options.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Lima, , Peru
Patients applied
Trial Officials
Santiago Munne, PhD
Principal Investigator
Reprogenetics
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials